AU2008227100B2 - Pyridazinone derivatives useful as glucan synthase inhibitors - Google Patents

Pyridazinone derivatives useful as glucan synthase inhibitors Download PDF

Info

Publication number
AU2008227100B2
AU2008227100B2 AU2008227100A AU2008227100A AU2008227100B2 AU 2008227100 B2 AU2008227100 B2 AU 2008227100B2 AU 2008227100 A AU2008227100 A AU 2008227100A AU 2008227100 A AU2008227100 A AU 2008227100A AU 2008227100 B2 AU2008227100 B2 AU 2008227100B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
candida
spp
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008227100A
Other languages
English (en)
Other versions
AU2008227100A1 (en
Inventor
Robert G. Aslanian
Jianhua Cao
Robert Jason Herr
David Won-Shik Kim
Rongze Kuang
Pauline C. Ting
Heping Wu
Jinhai Yang
Gang Zhou
Nicolas Zorn
Andrew John Zych
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Curia Global Inc
Original Assignee
Merck Sharp and Dohme Ltd
Albany Molecular Research Inc
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Albany Molecular Research Inc, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2008227100A1 publication Critical patent/AU2008227100A1/en
Assigned to MERCK SHARP & DOHME CORP., ALBANY MOLECULAR RESEARCH, INC. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: ALBANY MOLECULAR RESEARCH, INC., SCHERING CORPORATION
Application granted granted Critical
Publication of AU2008227100B2 publication Critical patent/AU2008227100B2/en
Priority to AU2014201996A priority Critical patent/AU2014201996A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2008227100A 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors Ceased AU2008227100B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201996A AU2014201996A1 (en) 2007-03-15 2014-04-08 Pyridazinone derivatives useful as glucan synthase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91817107P 2007-03-15 2007-03-15
US60/918,171 2007-03-15
PCT/US2008/003257 WO2008115381A1 (en) 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201996A Division AU2014201996A1 (en) 2007-03-15 2014-04-08 Pyridazinone derivatives useful as glucan synthase inhibitors

Publications (2)

Publication Number Publication Date
AU2008227100A1 AU2008227100A1 (en) 2008-09-25
AU2008227100B2 true AU2008227100B2 (en) 2014-01-09

Family

ID=39525788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008227100A Ceased AU2008227100B2 (en) 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors

Country Status (18)

Country Link
US (1) US8232274B2 (OSRAM)
EP (2) EP2586778A3 (OSRAM)
JP (3) JP5147866B2 (OSRAM)
KR (1) KR20100049500A (OSRAM)
CN (1) CN101730692A (OSRAM)
AR (1) AR065721A1 (OSRAM)
AU (1) AU2008227100B2 (OSRAM)
BR (1) BRPI0809238A2 (OSRAM)
CA (1) CA2680583A1 (OSRAM)
CL (1) CL2008000725A1 (OSRAM)
CO (1) CO6220966A2 (OSRAM)
EC (1) ECSP099634A (OSRAM)
IL (1) IL200906A0 (OSRAM)
MX (1) MX2009009948A (OSRAM)
PE (1) PE20081882A1 (OSRAM)
RU (1) RU2009137946A (OSRAM)
TW (1) TW200902516A (OSRAM)
WO (1) WO2008115381A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809193A2 (pt) 2007-03-15 2014-09-23 Novartis Ag Compostos orgânicos e seus usos
CN101668529A (zh) * 2007-03-15 2010-03-10 先灵公司 用作葡聚糖合成酶抑制剂的哌嗪取代的哒嗪酮衍生物
CN101801954B (zh) * 2007-09-20 2013-10-09 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2814011A1 (en) * 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013073577A1 (ja) 2011-11-15 2013-05-23 アステラス製薬株式会社 ジヒドロキシ芳香族へテロ環化合物
WO2013155223A1 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN103664795B (zh) * 2012-09-06 2017-10-03 华东理工大学 哒嗪酮类化合物及其用途
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN104717924A (zh) 2012-10-05 2015-06-17 皇家飞利浦有限公司 用于提供增强的x射线图像的医学成像系统及方法
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
JP2017517498A (ja) * 2014-04-24 2017-06-29 ヘキシマ リミテッド 薬剤および治療方法
EP3426029B1 (en) 2016-03-07 2023-08-30 AgroFresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
AU2018235937A1 (en) 2017-03-15 2019-09-19 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2018185013A1 (en) 2017-04-03 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CA3075727A1 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
CN109912476A (zh) * 2019-03-27 2019-06-21 南通宝凯化工有限公司 一种异丙氨基磺酰氯的生产工艺
TW202115042A (zh) * 2019-06-21 2021-04-16 大陸商江蘇豪森藥業集團有限公司 芳基磷氧化物類衍生物抑制劑、其製備方法和應用
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
WO2023204124A1 (ja) * 2022-04-20 2023-10-26 日本曹達株式会社 ピリダジノン化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
CA2482151A1 (en) * 2002-04-12 2003-11-27 Bayer Healthcare Ag Substituted 2-phenyl-3(2h)-pyridazinones

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS565734B2 (OSRAM) * 1973-02-28 1981-02-06
DE3048487A1 (de) * 1980-12-22 1982-07-29 Cassella Ag, 6000 Frankfurt Basisch substituierte pyridazine, ihre herstellung und ihre verwendung
ES540813A0 (es) 1985-02-28 1985-11-16 Abello Quimicos Farma Prod Sa Procedimiento de obtencion de 1,2-diazin-3 (2h)-onas con interes farmaceutico
GB2256587A (en) 1991-06-11 1992-12-16 American Cyanamid Co Acetazolamide in sustained release form
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
EP1479681A4 (en) 2002-01-31 2006-05-10 Daiichi Seiyaku Co IMIDAZO (1,2-a) pyridine
US20050209278A1 (en) * 2002-04-25 2005-09-22 Mcdonald Joseph J Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
ATE495155T1 (de) * 2003-11-19 2011-01-15 Array Biopharma Inc Heterocyclische inhibitoren von mek
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
GB0524991D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
CN101668529A (zh) * 2007-03-15 2010-03-10 先灵公司 用作葡聚糖合成酶抑制剂的哌嗪取代的哒嗪酮衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
CA2482151A1 (en) * 2002-04-12 2003-11-27 Bayer Healthcare Ag Substituted 2-phenyl-3(2h)-pyridazinones

Also Published As

Publication number Publication date
MX2009009948A (es) 2009-09-24
ECSP099634A (es) 2009-10-30
AR065721A1 (es) 2009-06-24
PE20081882A1 (es) 2008-12-27
EP2586778A2 (en) 2013-05-01
EP2586778A3 (en) 2013-07-31
RU2009137946A (ru) 2011-04-20
BRPI0809238A2 (pt) 2014-09-09
EP2137179A1 (en) 2009-12-30
CN101730692A (zh) 2010-06-09
JP5147866B2 (ja) 2013-02-20
CO6220966A2 (es) 2010-11-19
AU2008227100A1 (en) 2008-09-25
US20090170861A1 (en) 2009-07-02
CA2680583A1 (en) 2008-09-25
EP2137179B1 (en) 2015-09-02
CL2008000725A1 (es) 2008-11-14
WO2008115381A1 (en) 2008-09-25
KR20100049500A (ko) 2010-05-12
JP2013014622A (ja) 2013-01-24
TW200902516A (en) 2009-01-16
JP2014051529A (ja) 2014-03-20
IL200906A0 (en) 2010-05-17
US8232274B2 (en) 2012-07-31
JP2010521461A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
AU2008227100B2 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
US8022088B2 (en) Substituted bicyclic and tricyclic thrombin receptor antagonists
JP5241834B2 (ja) プロテインキナーゼ阻害剤としての複素環アミド化合物
EP2217611B1 (en) Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP3129380B1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
EP2819996B1 (en) 6-alkynyl pyridines as smac mimetics
AU2008282885A1 (en) Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
CA3071143A1 (en) Novel compounds
CA2680587A1 (en) Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
US20070232635A1 (en) Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists
CN107001385A (zh) 作为mdm2‑p53抑制剂的新的螺‑[3h‑吲哚‑3,2’‑吡咯烷]‑2(1h)‑酮化合物及其衍生物
AU2007269836A1 (en) Substituted piperidines that increase P53 activity and the uses thereof
KR20110033239A (ko) 단백질 키나제 억제제
WO2009097233A9 (en) Imidazopyrazines as protein kinase inhibitors
EP3157922B1 (en) Pyrazolo-pyridine derivatives as kinase inhibitors
AU2020413555B2 (en) PD-L1 antagonist compound
WO2007075809A2 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
CN116836167B (zh) 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
AU2014201996A1 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
CN116848103A (zh) 高活性hpk1激酶抑制剂
CN102869663A (zh) 吡唑并吡嗪激酶抑制剂
CA3000063C (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
HK30089209A2 (en) Hpk1 kinase inhibitor compound
HK30089210A2 (en) A highly active wnt pathway inhibitor compound
AU2006302435A1 (en) Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired